Increased stomach cancer risk following radiotherapy for testicular cancer

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 44-51

  Hauptmann, M ^a   Fossa, S D ^b   Stovall, M ^c   Van Leeuwen, F E ^a   Johannesen, T B ^d   Rajaraman, P ^e   Gilbert, E S ^e   Smith, S A ^c   Weathers, R E ^c   Aleman, B M P ^a   Andersson, M ^f   Curtis, R E ^e   Dores, G M ^e,g   Fraumeni, J F ^e   Hall, P ^h   Holowaty, E J ⁱ   Joensuu, H ^j   Kaijser, M ^h   Kleinerman, R A ^e   Langmark, F ^d   Lynch, C F ^k   Pukkala, E ^l,m   Storm, H H ⁿ   Vaalavirta, L ^j   Van Den Belt Dusebout, A W ^a   Travis, L B ^o   Morton, L M ^e   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TEXAS   (United States)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Mental Health Center Glostrup   (Denmark)

^g Affairs Medical Center   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY OF IOWA   (United States)

^l FINNISH CANCER REGISTRY   (Finland)

^m TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁿ DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^o UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

chemotherapy; radiotherapy; stomach cancer; testicular cancer

Indexed keywords

ALKYLATING AGENT; CISPLATIN; GYRASE INHIBITOR; VINCA ALKALOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RISK ASSESSMENT; STOMACH CANCER; TESTIS CANCER; ADOLESCENT; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; INCIDENCE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; RADIATION DOSE; RADIATION RESPONSE; STOMACH NEOPLASMS; SURVIVOR; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; RADIOTHERAPY DOSAGE; STOMACH NEOPLASMS; SURVIVORS; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84920680761     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.552     Document Type: Article

References (49)

1. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ (2012) Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 84(2): 383-389.
2. Berrington de Gonzalez A, Gilbert E, Curtis R, Inskip P, Kleinerman R, Morton L, Rajaraman P, Little MP (2013) Second solid cancers after radiation therapy: A systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 86(2): 224-233.
3. Biggs ML, Schwartz SM (2007) Cancer of the testis. In: Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (eds) SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, pp 175-180.
4. Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT (1997) Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 37: 67-73.
5. Brenner H, Rothenbacher D, Arndt V (2009) Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477.
6. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research: Volume 1 - The Analysis of Case-Control Studies. International Agency for Research on Cancer: Lyon.
7. Carr JD, Kleinerman RA, Stovall M, Weinstock M, Griem ML, Land CE (2002) Malignant neoplasms after radiation therapy for peptic ulcer. Radiat Res 157: 668-677.
8. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA (2010) International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Pre 19(5): 1151-1159.
9. Dowd SB, Wilson BG (1995) Encyclopedia of Radiographic Positioning. Vol. 2. Saunders: Philadelphia, PA.
10. Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3): 293-298.
11. Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20(4): 633-649.
12. Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002) Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 13: 1786-1791.
13. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a populationbased study. J Clin Oncol 31(30): 3807-3814.
14. Garner MJ, Turner MC, Ghadirian P, Krewski D (2005) Epidemiology of testicular cancer: an overview. Int J Cancer 116(3): 331-339.
15. Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6): 695-706.
16. Henderson TO, Oeffinger KC, Whitton J, Leisenring W, Neglia J, Meadows A, Crotty C, Rubin DT, Diller L, Inskip P, Smith SA, Stovall M, Constine LS, Hammond S, Armstrong GT, Robison LL, Nathan PC (2012) Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 156(11): 757-766.
17. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV (2008) Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 26: 3937-3942.
18. Horwich A, Fossa S, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110: 256-263.
19. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/1975-2010/based on November 2012 SEER data submission, posted to the SEER website, April 2013.
20. International Agency for Research on Cancer (2004) Tobacco Smoke and Involuntary Smoking. IARC: Lyon.
21. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6): 1200-1208.
22. Kleinerman RA, Smith SA, Holowaty E, Hall P, Pukkala E, Vaalavirta L, Stovall M, Weathers R, Gilbert E, Aleman BM, Kaijser M, Andersson M, Storm H, Joensuu H, Lynch CF, Dores GM, Travis LB, Morton LM, Curtis RE (2013) Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancer. Int J Radiat Oncol Biol Phys 86(5): 922-929.
23. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C (1999) Therapyrelated malignancies following treatment of germ cell cancer. Int J Cancer 83: 860-863.
24. Leibel SA, Phillips TL (2004) Textbook of Radiation Oncology. 2nd edn. Saunders: Philadelphia, PA.
25. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 87: 3625-3632.
26. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97(1): 63-70.
27. Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Hodgson DC, Storm HH, Johannesen TB, Smith SA, Weathers RE, Andersson M, Fossa SD, Hauptmann M, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta L, van den Belt-Dusebout AW, Fraumeni Jr JF, Travis LB, Aleman BM, van Leeuwen FE (2013) Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 31(27): 3369-3377.
28. National Comprehensive Cancer Network (NCCN) (2013) Clinical Practice Guidelines in Oncology. Testicular Cancer. Version 1.2013, www.NCCN.org.
29. National Council on Radiation Protection and Measurements Scientific Committee 1-17 (2011) Second Primary Cancers and Cardiovascular Disease After Radiotherapy. NCRP Report No. 170. National Council on Radiation Protection and Measurements: Bethesda, MD.
30. Nomura A (1996) Stomach cancer. In Cancer Epidemiology and Prevention, Schottenfeld D, Fraumeni JF (eds) 2nd edn Chapter 34. pp 707-724. Oxford University Press: New York.
31. Preston DL, Lubin JH, Pierce DA, McConney MA (1993) Epicure: User's Guide. Hiro Soft International Corporation: Seattle, WA.
32. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K (2007) Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168: 1-64.
33. Robinson D, Moller H, Horwich A (2007) Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96: 529-533.
34. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. ESMO Guidelines Working Group (2009) Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4): 83-88.
35. Stovall M, Weathers R, Kasper C, Smith SA, Travis L, Ron E, Kleinerman R (2006) Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies. Radiat Res 166: 141-157.
36. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18: 498-509.
37. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni Jr JF, Boice Jr JD (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429-1439.
38. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340(5): 351-357.
39. Travis LB, Andersson M, Gospodarowicz M, Van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice Jr JD, Stovall M, Gilbert E (2000) Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92(14): 1165-1171.
40. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice Jr JD, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18): 1354-1365.
41. Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice Jr JD (2012) Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104(5): 357-370.
42. Van den Belt-Dusebout AW, De Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, Van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25(28): 4370-4378.
43. Van den Belt-Dusebout AW, Aleman BM, Besseling G, de Bruin ML, Hauptmann M, Van 't Veer MB, De Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE (2009) Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 75: 1420-1429.
44. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerkhoff EH, Delemarre JF, Somers R (1993) Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 11: 415-424.
45. Van Leeuwen FE, Klokman WJ, Van 't Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, Van Heerde P, Burgers JM, Somers R, Aleman BM (2000) Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18: 487-497.
46. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. EUROCARE-4 Working Group (2007) Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8(9): 784-796.
47. Weiss HA, Darby SC, Doll R (1994) Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 59(3): 327-338.
48. Wilson CL, Ness KK, Neglia JP, Hammond S, Shnorhavorian M, Leisenring WL, Stovall M, Robison LL, Armstrong GT (2013) Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 105(7): 504-508.
49. Yu HY, Madison RA, Setodji CM, Saigal CS (2009) Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 27: 4327-4332.